The recent article by Cimba et al raises an important question that has not been fully answered by the current literature.1 Pediatric patients affected by various skeletal disorders have received antiresorptive medications since around 1998.2 Historically, pamidronate has been the treatment of choice with a recent shift to zoledronate. To date, there have been no reported cases of medication related osteonecrosis of the jaws (MRONJ) in the pediatric population. The reason for this has not been fully elucidated. (Source: Journal of Oral and Maxillofacial Surgery)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου